One month after a STEMI, should my female patient continue fondaparinux sodium 2.5 mg daily, or discontinue it and use other antiplatelet/anticoagulant therapy?

Discontinue Fondaparinux Immediately

Your patient should stop fondaparinux now—it has no role in post-STEMI management beyond the acute hospitalization period. One month after STEMI, she should be on dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor), not an anticoagulant like fondaparinux.

Why Fondaparinux Must Be Stopped

Guideline-Based Recommendations

The 2013 ACC/AHA STEMI guidelines are explicit about fondaparinux use 1, 2:

• Fondaparinux is contraindicated as the sole anticoagulant during PCI (Class III: Harm) due to catheter thrombosis risk
• Anticoagulation should be discontinued after PCI for uncomplicated cases 1
• For medical management without PCI, fondaparinux is continued only for the duration of hospitalization, up to 8 days maximum 3, 4, 5

The 2018 ESC STEMI guidelines similarly state that fondaparinux is not recommended for primary PCI (Class III) 6.

What She Should Be Taking Instead

Standard post-STEMI antiplatelet therapy 1, 7, 8:

1. Aspirin 81 mg daily indefinitely (Class I, Level A)

   • Continue this for life unless contraindicated

2. P2Y12 inhibitor for 12 months minimum (Class I):

   • Ticagrelor 90 mg twice daily (preferred), OR
   • Prasugrel 10 mg daily (if no prior stroke/TIA), OR
   • Clopidogrel 75 mg daily (if the above are unavailable/contraindicated)

3. Additional anticoagulation ONLY if specific indications exist 7:

   • Atrial fibrillation requiring warfarin (INR 2.0-3.0)
   • Left ventricular thrombus documented on echo
   • If triple therapy needed (aspirin + P2Y12 inhibitor + warfarin), use low-dose aspirin 75-81 mg with clopidogrel 75 mg and target INR 2.0-2.5 to minimize bleeding risk

Clinical Reasoning

The Evidence Against Continued Fondaparinux

The OASIS-6 trial 9, 10 demonstrated fondaparinux benefit in acute STEMI management (up to 8 days), showing reduced mortality and reinfarction without increased bleeding. However:

• Benefits were seen primarily in patients not undergoing primary PCI 9, 11, 12
• The drug was given for a maximum of 8 days in the trial
• No evidence supports long-term fondaparinux use post-STEMI

A recent Chinese study 13 compared fondaparinux to enoxaparin during hospitalization only, not for chronic therapy. The 2024 guideline review 14 confirms fondaparinux is for acute VTE prophylaxis/treatment, not chronic post-MI management.

Bleeding Risk Considerations

Continuing fondaparinux unnecessarily exposes your patient to:

• Increased bleeding risk without proven benefit 15
• Renal accumulation if kidney function declines (fondaparinux is renally cleared)
• No antidote available if major bleeding occurs 15, 14

The FDA label 15 emphasizes fondaparinux is for acute thromboprophylaxis (orthopedic surgery, DVT/PE treatment), not chronic post-MI therapy.

Immediate Action Plan

1. Stop fondaparinux today
2. Verify she is on appropriate DAPT:
   • Aspirin 81 mg daily
   • P2Y12 inhibitor (preferably ticagrelor or prasugrel) for at least 12 months post-STEMI
3. Assess for anticoagulation indications:
   • Order echocardiogram if not done recently to rule out LV thrombus
   • Check for atrial fibrillation (ECG, telemetry review)
   • If neither present, no anticoagulation needed
4. Monitor renal function given fondaparinux's renal clearance 15

Common Pitfall to Avoid

Do not confuse acute anticoagulation (during hospitalization) with chronic secondary prevention. Fondaparinux played a role in the acute phase if she didn't undergo primary PCI or received fibrinolysis 11, 12, but that indication ended when she left the hospital. The 2025 ACC/AHA ACS guidelines 16 confirm anticoagulation is discontinued after uncomplicated PCI.